# Randomised controlled trial of carvedilol versus variceal band ligation in the primary prophylaxis of oesophageal variceal haemorrhage

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
09/06/2007		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
05/07/2007	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
21/09/2009	Digestive System			

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

**Prof Peter Hayes** 

#### Contact details

Department of Hepatology University of Edinburgh Little France Edinburgh United Kingdom EH16 4SA +44 (0)131 242 1625 p.hayes@ed.ac.uk

# Additional identifiers

EudraCT/CTIS number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

# Study information

#### Scientific Title

#### Study objectives

Carvedilol, a vasodilating non-selective beta blocker is more effective than variceal band ligation in the prevention of the first variceal bleed in patients with high risk varices.

#### Ethics approval required

Old ethics approval format

## Ethics approval(s)

Ethical approval obtained from Lothian Research Ethics Committee on 14th February 2000.

#### Study design

Prospective multicentre randomised controlled clinical trial

#### Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

# Study type(s)

Treatment

#### Participant information sheet

# Health condition(s) or problem(s) studied

Cirrhosis and portal hypertension

#### **Interventions**

- 1. Carvedilol starting at 6.25 mg per day for a week, to increase to 12.5 per day thereafter if tolerated
- 2. Variceal band ligation to be performed every two weeks until variceal eradication

The follow up periods for the carvedilol and banding arms are  $23.3 \pm 21.1$  months and  $22.1 \pm 22.3$  months respectively.

### Intervention Type

Drug

#### Phase

**Not Specified** 

# Drug/device/biological/vaccine name(s)

Carvedilol

#### Primary outcome measure

The first variceal bleed.

The outcomes were measured for the entire follow up period and also at 6, 12, and 24 months.

#### Secondary outcome measures

- 1. Overall mortality
- 2. Variceal bleeding related mortality
- 3. Adverse events leading to treatment discontinuation

The outcomes were measured for the entire follow up period and also at 6, 12, and 24 months. Bleeding induced mortality was defined as death within 6 weeks of the index variceal bleed.

#### Overall study start date

14/02/2000

## Completion date

24/05/2006

# Eligibility

#### Key inclusion criteria

Liver cirrhosis and the presence of Grade II or larger oesophageal varices.

# Participant type(s)

Patient

# Age group

Adult

#### Sex

**Not Specified** 

# Target number of participants

152

# Key exclusion criteria

- 1. Aged less than 18 or greater than 75
- 2. Medication: vasoactive drugs such as beta blockers or nitrates
- 3. Advanced cardiopulmonary disease
- 4. Malignancy with prognosis that will affect study outcome
- 5. Allergy to carvedilol
- 6. Patients with obstructive airways disease

#### Date of first enrolment

14/02/2000

# Date of final enrolment

24/05/2006

# Locations

## Countries of recruitment

Scotland

**United Kingdom** 

Study participating centre
Department of Hepatology
Edinburgh
United Kingdom

EH16 4SA

# Sponsor information

# Organisation

University of Edinburgh (UK)

# Sponsor details

Royal Infirmary Little France Edinburgh Scotland United Kingdom EH16 4SB mvm@ed.ac.uk

# Sponsor type

University/education

#### Website

http://www.ed.ac.uk/

#### **ROR**

https://ror.org/01nrxwf90

# Funder(s)

# Funder type

University/education

#### **Funder Name**

University of Edinburgh (UK)

#### Alternative Name(s)

Universitas Academica Edinburgensis, Oilthigh Dhùn Èideann, The University of Edinburgh, University of Edinburgh in United Kingdom, Edin, Tounis College, King James' College, Athens of the North, ED, Edin

# **Funding Body Type**

Government organisation

#### Funding Body Subtype

Universities (academic only)

#### Location

**United Kingdom** 

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2009		Yes	No